ZORYVE CREAM
(roflumilast)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background
Zoryve (roflumilast) is an inhibitor of phosphodiesterase 4 (PDE4). Inhibition of PDE4 leads to accumulation of intracellular cyclic AMP. The specific mechanism by which Zoryve exerts its therapeutic action is not well defined (1).

Regulatory Status
FDA-approved indication: Zoryve is a phosphodiesterase 4 inhibitor indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older (1).

The safety and effectiveness of Zoryve in pediatric patients less than 12 years of age have not been established (1).

Summary
Zoryve (roflumilast) is an inhibitor of phosphodiesterase 4 (PDE4). Zoryve is indicated for use in patients with plaque psoriasis (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Zoryve while maintaining optimal therapeutic outcomes.

References